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Abstract
Background
For winter 2003/2004 in Scotland, it was recommended that all those aged 65 and
over be eligible to receive 23-valent polysaccharide pneumococcal vaccine (23vPPV),
which has been shown to be effective in reducing the risk of invasive pneumococcal
disease (IPD). We assessed the success of the vaccination programme by examining
the age specific incidence rates of IPD compared to four previous winter seasons and
estimating vaccination effectiveness.
Methods
Winter season incidence rates of IPD for vaccine targeted (65 years and over) and
non-targeted (0-4, 5-34, 35-49, 50-64) age bands were examined for the Scottish
population in a retrospective cohort design for winter 2003/2004. Details of all IPD
cases were obtained from the central reference laboratory and population vaccine
uptake information was estimated from a GP sentinel practice network. Based on the
preceding four winter seasons, standardised incidence ratios (SIR) for invasive
pneumococcal disease were determined by age-band and sex during winter
2003/2004. Vaccination effectiveness (VE) was estimated using both screening and
indirect cohort methods. Numbers needed to vaccinate were derived from VE results
using equivalent annual incidence estimates for winter 2003/2004.
Results
Overall vaccination effectiveness using the screening method (adjusted for age and
sex) in those aged 65 and over was 61.7% (95%CI: 45.1, 73.2) which corresponded to
a number needed to vaccinate of 5206 (95%CI: 4388, 7122) per IPD case prevented.
Estimated effectiveness for the same age group using the indirect cohort method was
not significant at 51% (95%CI: -278, 94). Reductions in the winter season incidence
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rate of IPD were highly significant for all those aged 75+: males SIR=58.8 (95%CI:
41.6, 80.8); females SIR=70.0 (95%CI: 55.1, 87.8). In the 65-74 years age-group, the
reduction for females was significant: SIR=60.3 (95%CI: 39.3, 88.4), but not for
males: SIR=74.8 (95%CI: 50.8, 106.3). There was no significant protective effect on
mortality.
Conclusions
The introduction of 23vPPV for those aged 65 and over in Scotland during winter
2003/2004, was accompanied with a reduction of around one third in the incidence of
IPD in this age group. Vaccination effectiveness estimates were comparable with
those from other developed countries.
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Background
Streptococcus pneumoniae is one of the leading causes of bacteraemia and meningitis
in the United Kingdom and in public health terms remains one of the most important
bacterial pathogens worldwide [1]. While the incidence of invasive pneumococcal
disease (IPD) is highest in very young children, the elderly and persons with
underlying medical conditions are also at increased risk and mortality is highest in
these groups [2, 3]. In developed countries in particular, the combination of an aging
population and rising levels of pneumococcal resistance to commonly used antibiotics
have focused attention on preventative vaccination [4].
The current pneumococcal polysaccharide vaccine (23vPPV), which consists of 23
serotype antigens corresponding to over 90% of all invasive disease isolates, has been
available since the early 1980’s [5]. Its efficacy was first established against
pneumococcal pneumonia in randomized controlled trials conducted amongst novice
gold-miners in South Africa [6]. The balance of the evidence from a subsequent
wealth of prospective and retrospective studies in immuno-competent older adults [7]
together with cost effectiveness evaluations in the US [8] and Europe [9] tends to
support the targeting of older age groups for vaccination as a worthwhile and cost
saving intervention. The most recent Cochrane review also concluded that 23vPPV
was effective against IPD although the evidence was not sufficient against pneumonia
[10].
In winter 2003/2004, 23vPPV was recommended for all those aged 65 and over in
Scotland and promoted in parallel with an influenza vaccination programme for the
same age group [11]. This approach was at variance with the phased three year
 5
introduction programme for ten year age-bands (beginning with those aged 85 and
over) that was adopted in England and Wales and completed in 2005/2006. The
experience seen in Scotland may therefore serve as an early indication of the UK wide
impact of the programme. Previous to the age targeted campaign, 23vPPV vaccine
had only been recommended for all persons over the age of two years who were at
increased risk of IPD due to any of the following underlying medical conditions:
asplenia or splenic dysfunction; chronic renal disease or nephrotic syndrome;
immunosuppression resulting from disease or treatment; chronic heart disease;
chronic lung disease; chronic liver disease including cirrhosis and diabetes mellitus
[12]. The two principal outcome measures by which the impact of the vaccination
campaign was assessed in this evaluation were firstly the extent to which there was a
reduction in the expected winter incidence of invasive disease in the target age-
groups, since this was the major rationale behind the policy and secondly, the
estimated vaccination effectiveness for those age 65 and over. During the time period
of this evaluation, 23vPPV was the only population level age-targeted intervention
against pneumococcal disease in Scotland since the 7-valent pneumococcal conjugate
vaccine (Prevenar) was not introduced into the childhood vaccination programme
until September 2006 [13].
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Methods
Study design, population and time period
The impact of the pneumococcal vaccination campaign in winter 2003/2004 was
evaluated using a retrospective cohort design which looked at vaccination
effectiveness and the age-specific incidence of IPD. The principle outcome measures
were observed changes in the 2003/2004 winter season incidence rates of IPD in the
vaccine targeted population of those aged 65 and over (divided into males and
females aged 65-74 and 75 and over). For comparison, the incidence rates of invasive
disease in younger age bands (0-4, 5-34, 35-49 and 50-64) were also examined for the
same winter season. Figure 1 gives an overview of the study design and data sources.
IPD incidence
Reports of all pneumococcal laboratory isolates from every diagnostic laboratory in
Scotland are collated at Health Protection Scotland (HPS). In an ongoing
collaboration with the Scottish Meningococcus and Pneumococcus Reference
Laboratory (SMPRL), surveillance for invasive pneumococcal disease (IPD) involves
obtaining laboratory confirmation, serotype identification and antibiotic resistance
profiling for all blood and CSF isolates. There were no changes in culture procedures
or in the criteria used by diagnostic laboratories to submit isolates over the period of
the study. Laboratory reports of pneumococcal infection for the winter seasons (weeks
40 of preceding year to week 20 of the following year) were extracted from the
national HPS database for 1999/2000; 2000/2001; 2001/2002; 2002/2003; 2003/2004.
Total IPD isolates (i.e.: blood and CSF) for these time periods were used to derive
winter season incidence rates by age-band (0-4, 5-34, 35-49, 50-64, 65-74 and 75+)
and sex. For ease of comparison with other published studies, crude annualised
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incidence rates were estimated by assigning a two-thirds weighting to the winter
season total (according to the mean proportion of annual cases which occur during
weeks 40 to 20).
Population totals were obtained from the General Register Office for Scotland
Statistics Library [14], the midyear estimates preceding each winter season being used
as denominators. To verify any continuing trends, incidence rates for winter
2004/2005 were also determined. A Poisson regression model, using the log
(population) as an offset variable was used to predict the expected number of cases for
winter season 2003/2004, from which were derived standardised incidence ratios
(SIR). The Poisson model used data on the incidence rates of the four preceding
winter seasons and included the following terms: winter season (continuous variable),
age group, sex and the interaction term of sex and age. The 95% confidence interval
(CI) for the SIR was calculated using the error factor and a Chi-square test was used
to compare numbers of observed and expected cases.
Vaccine uptake
Estimates of 23vPPV vaccine uptake in winter 2003/2004 across the whole population
were assessed through a sentinel surveillance network called the continuous morbidity
record (CMR), which covers a seven percent representative sample of the Scottish
population [15]. In contrast, influenza vaccine uptake data is not dependent on sample
population projections, since it is based on item of service returns collated by the
information and statistics division of NHS Health Services Scotland [16]. For every
patient with laboratory confirmed IPD in winter 2003/2004, the Scottish community
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health index (CHI) [17] was used to obtain the details of their general medical
practitioner / family doctor (GP). A postal questionnaire was then sent to confirm the
patient’s disease outcome, age, vaccination status with respect to both pneumococcal
disease (ever vaccinated) and influenza (for the 2003/2004 season) and the presence
of any underlying medical conditions deemed to present an increased risk of IPD [12].
For deceased patients whose records were no longer held within primary care,
permission to access medical notes was sought in writing from the respective NHS
boards (via Caldicott guardians). IPD cases were regarded as true vaccine failures if
the date of vaccination was at least 14 days prior to the sample date, or the GP reply
confirmed they had been vaccinated before the onset of their illness. For ethical
purposes the patient follow up work was not classified as research, but as an
evaluation of an ongoing vaccination programme. Chi-square tests for proportions
were used to compare differences in 23vPPV uptake between sexes and different risk
groups.
Estimation of vaccination effectiveness
Estimates of vaccination effectiveness (VE) using the screening method described by
Farrington [18] were derived by age-band (all 65+; 65-74 and all 75+) and sex using
CMR uptake data projected across the whole population. Stratified estimates were
obtained after separating patients classified as very high risk (VHR) which
incorporated asplenics and the severely immuno-compromised (haematological
malignancies and non-haematological malignancies who are currently receiving
cancer therapy). VE results were also expressed as numbers needed to vaccinate per
IPD case prevented. In addition, the indirect cohort method [19], which compares the
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proportions of pneumococcal infections caused by 23vPPV serotypes between
vaccinated and unvaccinated IPD cases, was also used to obtain an estimate of VE.
The method assumes vaccinated persons to be at the same risk of non-vaccine
serotype infections as unvaccinated persons and cross-reactivity was assumed for
serotypes closely related to vaccine components (e.g. 6A, 15C). Since the cohort
effectively covers the whole Scottish population and survival outcomes were available
from follow up, the relative risk of dying from pneumococcal disease could be
calculated according to vaccination status for the target age-groups. An ‘IPD related
fatality’ (i.e. most likely to have been a result of the pneumococcal disease episode)
was defined as a case where death had been reported as the outcome on receipt of the
sample by SMPRL, or where death was subsequently established to have occurred
within 14 days of sample date. Mortality within 14 days of first positive blood sample
corresponds to the time period adopted by the International Pneumococcal Study
Group in relation to death from pneumococcal bacteraemia [20].
Results
IPD incidence in winter season 2003/2004
There were a total of 442 cases of IPD in Scotland during the study period, 170 of
which occurred in those aged 65 and over. These correspond to equivalent annual
incidence rates of 11.7 per 100,000 overall and 31.1 per 100,000 for the 65+ age
group. For the model used to calculate standardised incidence rates there was no
reason to reject the hypothesis that the Poisson regression and the included terms
fitted the data (goodness-of-fit test P = 0.679). In winter 2003/2004 the observed
incidence of IPD cases was significantly less than expected (on the basis of trends
over the preceding four winter seasons) for the 65+ age group as a whole (34%
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reduction: SIR = 66.4; 95%CI: 56.8, 77.2) (Table 1). For specific age-bands within
the 65+ population, there was a significant reduction for the 75+ age group of both
sexes (male SIR= 58.8; 95%CI: 41.6, 80.8 and female SIR = 70.0; 95%CI: 55.1, 87.8)
and for females in the 65-74 age group (SIR = 60.3; 95%CI: 39.3, 88.4). Among
vaccine targeted age bands, the only reduction that did not achieve statistical
significance was for that males aged 65–74 (SIR = 74.8; 95% CI = 50.8, 106.3).
Vaccine uptake
Vaccine uptake estimates for the general population as obtained at the beginning of
December 2003 from CMR practices were 68.1% for males and 65.5% for females
(Table 2). This figure had altered little by the end of vaccination uptake monitoring
when the overall figure based on returns from general practice was 65% [21]. Of the
145 65+ IPD cases for whom vaccination status was known, 63(43.4%) had received
pneumococcal vaccine (34 out of 66 (51.5%) male cases and 29 out of 79 (36.7%)
female cases). The proportion of vaccine recipients among 65+ IPD cases was not
significantly different between those with or without respiratory disease (45% vs.
42.5% respectively, p = 0.760); those with or without cardiovascular disease (50% vs.
37.9%, p = 0.182) or those with or without ‘more than one risk factor’ (46.1% vs.
42.3%, p = 0.823).
Vaccine uptake rates in the CMR sample population were inversely associated with
the SIRs for both men and women (Figure 2). The significant reduction in the SIR
was only seen among vaccine targeted age groups with a correspondingly high
vaccine uptake. Out of a total of 448 isolates, 417 were successfully matched to
patient details through their community health index numbers and after exclusion of
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non-retrievable and mismatched records, 396 (88.4%) were available for follow up.
Of those matched records, 348 were completed for vaccination status and for the
presence of underlying risk factors including 145 (87.9%) of the 65+ cases. Table 3
shows the baseline statistics of completed records linked to patients with regard to
sex, age and proportion of VHR. Overall, 75 (21.6%) IPD cases had received
pneumococcal vaccination, with date of vaccination known for 71 (94.7%). Of these,
43 (60.6%) had received vaccine in 2003 or 2004. Out of a total of 60 23vPPV
vaccine recipients in patients aged 65 or over, 52 (86.7%) had also received influenza
vaccine for the 2003/2004 winter season. Among IPD patients, the percentage who
had received vaccine in all age groups was generally higher for males compared to
females (Table 2), although the difference was not statistically significant (p = 0.180).
A slightly higher vaccine uptake for males aged 65+ was also evident in the CMR
sample population. For the 65+ population as a whole, there was a steady increase in
the uptake of influenza vaccine over the course of the study period, rising from 64.9%
in winter 2001/2002 to 68.9% in 2002/2003 and 72.5% in 2003/2004 [16].
Vaccination effectiveness
The overall result obtained for crude vaccination effectiveness (VE) for the 65+ age
group was 64.2% (95% CI: 49.6, 74.5) and after adjustment for age and sex, the
revised estimate was 61.7% (95% CI: 45.1, 73.2). The adjusted figure corresponds to
a number needed to vaccinate (NNV) to prevent one IPD case of 5206 (95%CI: 4388,
7122). Table 4 shows VE results with 95% confidence limits for those aged 65+, 65-
74 and 75+ by sex after the exclusion of the VHR category. Sex differences in
effectiveness are apparent for the 65-74 age band at 64.6% for females (95%CI: 21.1,
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84.1) versus 41.0% (95%CI: -31.7, 73.6) for males, although these differences as well
as effectiveness in males were not statistically significant. Estimated VE for the VHR
subgroup who were aged 65 and over was also not significant at 37% (95%CI: -80,
70). The very low numbers of non-vaccine component strains in IPD patients (five out
of the six cases being in 65+ patients, three of whom were vaccinated) means that the
VE estimate by the indirect cohort method was associated with a high range of
uncertainty and did not reach statistical significance (VE (65+) = 51% (95% CI:-278,
94). Since the majority of IPD patients who had received pneumococcal vaccine also
received the current seasonal influenza vaccine, patient numbers were insufficient to
obtain a reliable estimate of vaccination effectiveness for pneumococcal vaccine
alone.
Serotype analysis and vaccine failures
Serotype confirmation was obtained for 388 (98%) of the 396 IPD isolates received in
winter 2003/2004. Of the 109 IPD cases aged 65+ for whom serotype was confirmed,
46 out of 48 (95.8%) of those vaccinated had 23vPPV strains as did 56 out of the 57
(98.2%) who had not been vaccinated. Of the three non-vaccine serotypes, serotypes
16 and 31 were found in vaccinated cases and serotype 34 in a non-vaccinated case.
For the whole dataset of IPD cases, 71 could be described as ‘true vaccine failures’,
nine of whom were classified as being very high risk (‘VHR’, see methods). A further
20 patients were known to have had more than one risk factor and overall 26 of the 71
(36.6%) were aged over 80 yrs.
Vaccination and IPD survival
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There were 70 IPD related fatalities overall, 50 of which occurred in those aged 65
and over and in which vaccination status was obtained for 44. Omitting the six cases
without vaccination details, the crude case fatality rate in the 65 plus age group was
27.0% for vaccinated patients and 32.9% for those who had not been vaccinated.
Based on estimated population uptake data, this translated into a NNV to prevent one
IPD related fatality of 14810 (Table 5). Since the reduced risk of dying as a result of
pneumococcal vaccination was not statistically significant, the NNV estimate can
only be seen as hypothetical. Crude relative risk reductions by age-band and sex for
those aged 65 and over (based on pneumococcal vaccination status alone), ranged
from 0.71 to 0.96 though none were statistically significant. There was also no
difference by sex or age-band (65-74 versus 75+).
Discussion
The introduction of 23-valent pneumococcal polysaccharide vaccine for those aged 65
and over in Scotland in winter 2003/2004 was accompanied with a significantly
reduced burden of invasive disease for this age group and an estimated VE
comparable with results seen elsewhere [22-24]. Although other studies have
demonstrated the effectiveness of this intervention in reducing the incidence of IPD,
high levels of chronic disease morbidity in Scotland [25] that are not simply confined
to qualifying medical conditions, meant that automatic assumptions about the likely
success of such a campaign were not possible at the outset. Preliminary incidence data
for winter 2004/2005, showing a continued reduced incidence of IPD in the 65+
population (equivalent annual incidence rate of 30.0/100,000 compared with 31.1 for
winter 2003/2004), is further testimony to the apparent success of the programme. A
marginal though inconclusive reduction in mortality risk was also suggested for IPD
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cases aged over 65 who had been vaccinated, although this was not statistically
significant for the one winter season analysed here. The NNV to prevent one case of
IPD in this evaluation (5206) is considerably lower than the recent Cochrane review
estimate of 20,000 although this was calculated for a 55 years and over population
where incidence would be much lower and is also based on a 50% vaccine
effectiveness [10]. Since the NNV estimates given here also used equivalent annual
incidence rates after the implementation of the vaccine programme, they can be
considered to be conservative.
While invasive pneumococcal disease accounts for only a small component of the
morbidity from the pneumococcus, it is at the more severe end of the clinical
spectrum and it is the outcome for which the evidence is strongest in showing a
protective effect from 23vPPV [26]. There is also a lack of ambiguity about a
laboratory isolate, which is not the case for ‘all cause pneumonia’ or ‘all cause
mortality’ which have also been used as indicator outcomes for assessing VE against
pneumococcal infection [27]. Additionally since the major rationale for the
pneumococcal vaccination campaign was aimed at reducing invasive disease and its
associated mortality and burden on health services, this was believed to be the most
legitimate means by which to evaluate the programme’s success or failure.
Observational studies can be said to assess the effects of health care interventions
without influencing the care that is provided or the patients who receive it [28]. When
used in the assessment of vaccination programmes therefore they have high external
validity and broad generalisability. In addition a number of randomised trials which
have sought to assess the effectiveness of 23vPPV have been insufficiently powered
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to detect real benefits and have therefore proven inconclusive, particularly with
respect to rare outcomes such as IPD [29]. Non-randomised studies such as the
current evaluation are limited by the extent to which there may be dissimilarities
between vaccinated and non-vaccinated persons, in both their likelihood of receiving
vaccination and in their subsequent care and follow up. Our findings that IPD patients
with respiratory disease, cardiovascular disease or more than one underlying chronic
health condition were no more likely to have received vaccine that those who did not,
provides some reassurance in this regard. Further reassurance can be derived from the
presumption that if vaccine recipients are more likely to be in poorer health, then the
reported benefits in this study would be an underestimate rather than an overestimate
of VE.
There are benefits as well as drawbacks to the evaluation of a pneumococcal vaccine
campaign based on just a single post-implementation winter season. While the effects
remain subject to between season variability according to temperature, airborne
pollutants and circulating respiratory viruses [30], the short time frame also minimises
differences in effect that may arise from changes in circulating serotypes and
variability in the duration of antibody response, which has been acknowledged as a
problem in elderly vaccine recipients [31]. With respect to circulating respiratory
viruses, the retrospective inclusion of all four previous winter seasons benefited from
known low levels of influenza (at or below seasonal baseline based on GP ‘flu-
spotter’ consultations) in each of those seasons and during the 2003/2004 season of
23vPPV implementation [32]. Marginal increases in influenza vaccination uptake
over the study period are therefore unlikely to have influenced the disease burden of
IPD. The fact that almost all vaccinated IPD patients also received influenza vaccine
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however means that we cannot exclude the possibility that there was some additive
benefit of both vaccines as has clearly been demonstrated by other authors [33, 34].
The one season post-implementation study design may also yield an over-optimistic
evaluation of VE that is not likely to be sustainable, due to both declining antibody
levels and the increased likelihood with time of encountering non-vaccine component
serotypes [35]. Additionally, the modest scale of the Scottish population makes it
feasible to centrally collate all cases of invasive pneumococcal disease allowing for
completeness of reporting and comparability between different years and winter
seasons. Retrospective ascertainment of vaccination status is of course less
dependable than prospective clarification, but the use of GP records is more reliable
than self-reporting methods [36] as is the electronic recording of uptake rates in the
sample CMR population.
In spite of our results being restricted to one winter season, it has been possible to
derive VE values in those aged 65 and over that compare well with other studies that
have also looked at IPD prevention [23, 37]. A high vaccine uptake in the first season
of implementation also means that any observed effect on the burden of disease is not
likely to be blurred by an annually increasing uptake rate, as has been postulated for
the US [38]. While substantial overlap between the confidence intervals makes it
difficult to interpret the variation in VE by sex and age-band, the finding of the
highest effectiveness being in the 75+ age category contrasts with the diminishing
effectiveness with age generally seen in other studies. For the Scottish population
however an element of survivor bias may be relevant, since the majority of those
surviving to 75+ years of age are from higher socio-economic groups [39]. The higher
effectiveness in females aged between 65 and 74 in spite of lower vaccine uptake,
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may reflect higher levels of underlying chronic illness in males of this age group
(although this is not evident from available risk factor data in this study, Table 3).
More severe underlying illness has also been linked with an increasing the likelihood
of opting for vaccination [40]. A slightly higher uptake of the pneumococcal plus flu
vaccine in older males, which is a combination known to have additive benefits [33],
may also have contributed to the high effectiveness in this sub-group although, as
noted previously, seasonal influenza activity was low throughout the study period.
The current estimate of VE by the indirect cohort method is characterised by a high
range of uncertainty although the actual value of 51% for those aged 65+ is not
incompatible with a protective effect. The multiple infecting serotypes of the
pneumococcal pathogen together with the high valency of 23vPPV mean that reliable
estimates using this method, such as that derived by Butler in the US [41], commonly
require large numbers of cases (specifically around 2400 gathered over a period of 14
years in that particular study). Single winter season estimates such as our own or that
determined in a recent Australian study [22] inevitably have low numbers of rare non-
vaccine serotypes which introduces a large margin of error.
The parallel targeting of pneumococcal vaccine with seasonal influenza has been
shown to be an effective means of achieving high uptake in pneumococcal
programmes for older adults [42] and the estimated overall uptake levels in the 65+
for the season under study (at 65%) also reflect the suitability of primary care as a
means of delivery. The recent Australian evaluation [22] reported reductions in IPD
incidence (36%) of similar magnitude to that seen in Scotland and VE estimates in the
same range as for the current study (71%: 95%CI: 54, 82). Similarly overall VE
estimates obtained from a case control study in Catalonia [23] were also in the same
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range (65%: 95%CI: 35, 81). These comparisons add a measure of confidence to the
generalisability of our results to other developed countries.
The inherent complexity of the pneumococcus and it’s sophistication in evading the
host immune response, requires that a high degree of vigilance at both the
epidemiological and microbiological levels continue to accompany the ongoing
implementation of this vaccine programme for older adults. A key issue in its medium
to long term success will be the duration of protective effect which several studies
have shown to decline rapidly in elderly subjects and in a manner that is not uniform
across all serotypes [27, 35]. The extent to which the elderly population may have
gained additional protection from the introduction of 7-valent conjugate vaccine
(PCV-7) to the childhood schedule from September 2006 [13] mediated through a
herd immunity effect [43], and as has shown promise in the US [44], awaits further
investigation. Protection against invasive disease is of course only one aspect of
tackling pneumococcal morbidity and the extent to which polysaccharide vaccine,
either alone or in combination with the new conjugate vaccines, might be able to
reduce pneumococcal pneumonia is the next key question in tackling the societal
burden of this pathogen. The evidence with regard to pneumonia is certainly less clear
cut and may need to await the development of more specific and efficient diagnostic
tests [45].
Conclusions
The introduction of pneumococcal polysaccharide vaccine for those aged 65 and over
in Scotland during winter 2003/2004 was associated with a reduction of around one
third in the incidence of invasive pneumococcal disease in this age group. Given the
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epidemiological diversity of the pneumococcus by population and by region [4],
policymakers ought to be encouraged that the VE estimates obtained are comparable
to those seen in other developed countries. Additionally, as the first large scale
demonstration of effectiveness in a UK population, the results should strengthen the
evidence base for health care practitioners involved in distributing vaccine in England
and Wales, now that the phased roll-out to all over 65s is complete. Joint influenza
and pneumococcal immunization in the primary healthcare setting is both effective
and widely acceptable as evidenced by high uptake rates, and should continue to be a
mainstay of disease prevention for this age group in years to come. Whether the
reduced incidence of invasive disease will persist for those aged 65 and over will only
be apparent when data for future years / winter seasons are analysed. Of course any
sustained change in serotype distribution towards non-vaccine component serotypes
may yet have significant implications for the current vaccination programme and its
longer term effectiveness.
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Figures
Figure 1. Study design and data sources
Figure 2. Standardised incidence ratios (SIR) for invasive pneumococcal disease
in winter 2003/04 with 95%CI limits and correlation with vaccine uptake rates#
by age-band and sex
Tables/…
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Table 1. IPD Standardised Incidence Ratios (SIR) for winter 2003/2004 by age-band and sex
Age group
(years)
Observed
cases
Expected
cases
SIR 95% CI
Chi-
square
test P-
value
Equivalent
annual
incidence
rates /
100,000
65+
Males
Females
69
101
106
150
65.2
67.1
50.7 - 82.6
54.7 – 81.6
<0.001**
<0.001**
30.85
31.33
65+ All 170 256 66.4 56.8 – 77.2 <0.001** 31.13
Males
0-4 36 30 118.4 82.9 -164.1 0.310 40.04
5-34 37 25 150.2 105.7 - 207.2 0.013* 5.79
35-49 37 39 95.0 66.8 -131.1 0.757 9.98
50-64 42 44 95.8 69.0 - 129.56 0.780 14.03
65-74 31 41 74.8 50.8 - 106.3 0.105 22.74
75+ 38 65 58.8 41.6 - 80.8 <0.001** 43.49
Females
0-4 27 18 152.2 100.2 - 221.8 0.028 31.41
5-34 32 16 204.8 140.0 - 289.4 <0.001* 5.05
35-49 26 20 129.4 84.4 - 189.8 0.188 6.62
50-64 35 42 83.9 58.4 - 116.8 0.298 11.16
65-74 26 43 60.3 39.3 - 88.4 0.009** 15.74
75+ 75 107 70.0 55.1 - 87.8 0.002** 47.72
* Significant increase from expected incidence rate produced by model
** Significant decrease from expected incidence rate produced by model
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Table 2. Percentage vaccine uptake by age-band and sex in CMR sample and IPD cases
CMR IPD
Age Male
% vaccine uptake
(total number in
group)
Female
% vaccine uptake
(total number in
group)
Male
% vaccine
uptake (total
number in
group#)
Female
% vaccine
uptake (total
number in
group#)
Age group (years)
0 – 4 0.3% (9,181) 0.2% (8,697) 7.7% (26) 5.3% (19)
5 – 34 0.8% (89,636) 0.9% (86,147) 8.0% (25) 5.6% (18)
35 – 49 2.7% (42,428) 3.0% (41,461) 4.5% (22) 3.7% (27)
50 – 64 9.9% (32,724) 10.5% (32,673) 9.4% (32) 2.9% (34)
65 – 74 66.7% (13.887) 65.3% (15,866) 53.8% (26) 42.3% (26)
75+ 70.5% (8,744) 65.7% (14,907) 50.0% (40) 34.0% (53)
All age 65+ years 68.1% (22,631) 65.5% (30,773) 51.5% (66) 36.7% (79)
Very high risk
No
Yes
- -
22.4% (161)
60.0% (10)
18.3% (164)
23.1% (13)
# Excluding unknown vaccination status
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Table 3. Baseline characteristics of IPD cases linked to patient records
Description IPD Cases
linked to
patient
records
Completed
Follow-up (%)
Vaccination
status known
(%)
With >1 Risk
factor (%) *
Number of subjects 396 368 348 61
Male (%) 198 (50.0) 181 (49.2) 171 (49.1) 28 (45.9)
Aged 65 + years (%) 165 (41.7) 156 (42.4) 145 (41.7) 43 (70.5)
% VHR§ - 29 (7.9) 23 (6.6) -
*
With >1 risk factor: more than one known risk factor for pneumococcal disease as set out in non-age
dependent criteria to be eligible for polysaccharide vaccine [12].
§ VHR denotes IPD cases in the very high risk category – defined as asplenics and the severely
immuno-compromised (haematological malignancies and non-haematological malignancies who are
currently receiving cancer therapy).
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Table 4. Vaccination effectiveness in those age 65 years and over (excluding very high risk)
with equivalent number needed to vaccinate (NNV) estimates
Group
Number of
vaccinated
cases
Total
number
of cases
% Vaccination
Effectiveness
(95% CI)
Equivalent Number
Needed to Vaccinate
# (NNV) with 95%
CI
Age 65+ years
All
Crude
Adjust
(Age/Sex)
Male
Female
57
30
27
135
59
76
64.2 (49.6, 74.5)
61.7 (45.1, 73.2)
53.5 (22.5, 72.1)
71.1 (53.7, 81.9)
-
5206 (4388, 7122)
6059 (4499, 14407)
9835 (3987, 5944)
Age 65-74 years
All
Male
Female
23
13
10
49
24
25
54.4 (20.1, 74.0)
41.0 (-31.7, 73.6)
64.6 (21.1, 84.1)
9724 (7148, 26317)
(10726) §
9835 (7554, 30110)
Age 75+ years
All
Male
Female
34
17
17
86
35
51
68.8 (52.0, 79.8)
60.5 (23.3, 79.6)
73.9 (53.3, 85.4)
3145 (2712, 4162)
3801 (2895, 9891)
2836 (2454, 3932)
* Vaccination effectiveness as determined by the screening method (see Methods)
# NNV: number needed to vaccinate to prevent one case (calculated as 1/attributable risk; based on equivalent annual
incidence of IPD in 2003/2004
§ Hypothetical value for NNV given non-significant test result
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Table 5. Pneumococcal vaccination status and relative risk (RR) of mortality in
patients aged 65 years and over
Group Total
no. in
group
%
Died
RR Mortality
(95% CI)
Crude
RR (95% CI)
adjusted for
age group
and gender
NNV§ to
prevent
1 death
All age 65+ years
No vaccine
Vaccine
82
63
32.9
28.6
1.00
0.86 (0.47, 1.56)
1.00
0.89
(0.49, 1.63)
14,810
Age group (years)
65-74
No vaccine
Vaccine
27
25
22.2
16.0
1.00
0.71 (0.20, 2.51)
- 39,172
75+
No vaccine
Vaccine
55
38
38.2
36.8
1.00
0.96 (0.49, 1.89)
- 8,122
Gender
Males
No vaccine
Vaccine
31
34
32.3
29.4
1.00
0.90 (0.38, 2.17)
-
Females
No vaccine
Vaccine
51
29
33.3
27.6
1.00
0.81 (0.35, 1.89)
-
§ NNV: Number needed to vaccinate to prevent 1 death. Note: since the reduction in mortality risk was
not significant, these are hypothetical estimates included only for comparison purposes.
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CMR sentinel surveillance
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